Outcomes of patients with Barrett's oesophagus with low-grade dysplasia undergoing endoscopic surveillance in a tertiary centre: a retrospective cohort study.
Barrett's oesophagus
low‐grade dysplasia
metaplasia
neoplasia
oesophageal neoplasm
upper gastrointestinal endoscopy
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
received:
12
10
2023
accepted:
29
08
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
20
9
2024
Statut:
aheadofprint
Résumé
Barrett's oesophagus predisposes individuals to oesophageal adenocarcinoma (OAC), with the risk of progression to malignancy increasing with the degree of dysplasia, categorized as either low-grade dysplasia (LGD) or high-grade dysplasia (HGD). The reported incidence of progression to OAC in LGD ranges from 0.02% to 11.43% per annum. In patients with LGD, Australian guidelines recommend 6-monthly endoscopic surveillance. We aimed to describe the surveillance practices within a tertiary centre, and to determine the predictive value of surveillance as well as other risk factors for progression. Endoscopy and pathology databases were searched over a 10-year period to collate all cases of Barrett's oesophagus with LGD. Medical records were reviewed to document patient factors and endoscopic and histologic details. Because follow-up times varied greatly, survival analysis techniques were employed. Fifty-nine patients were found to have LGD. Thirteen patients (22.0%) progressed to either HGD or OAC (10 (16.9%) and three (5.1%) respectively); the annual incidence rates of progression to HGD/OAC and OAC were 5.5% and 1.1% respectively. All patients who developed OAC had non-guideline-adherent surveillance. A Cox model found only two predictors of progression: (i) guideline-adherent surveillance, performed in 16 (27.1%), detected progression to HGD/OAC four times earlier than non-guideline-adherent surveillance (95% confidence interval (CI) = 1.3-12.3; P = 0.016). (ii) The detection of visible lesions at exit endoscopy independently predicted progression (hazard ratio = 6.5; 95% CI = 1.9-22.8; P = 0.003). Barrett's oesophagus with LGD poses a significant risk of progression to HGD/OAC. Guideline-recommended surveillance is effective, but is difficult to adhere to. Clinical predictors for those who are more likely to progress are yet to be defined.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Barrett's oesophagus predisposes individuals to oesophageal adenocarcinoma (OAC), with the risk of progression to malignancy increasing with the degree of dysplasia, categorized as either low-grade dysplasia (LGD) or high-grade dysplasia (HGD). The reported incidence of progression to OAC in LGD ranges from 0.02% to 11.43% per annum. In patients with LGD, Australian guidelines recommend 6-monthly endoscopic surveillance. We aimed to describe the surveillance practices within a tertiary centre, and to determine the predictive value of surveillance as well as other risk factors for progression.
METHODS
METHODS
Endoscopy and pathology databases were searched over a 10-year period to collate all cases of Barrett's oesophagus with LGD. Medical records were reviewed to document patient factors and endoscopic and histologic details. Because follow-up times varied greatly, survival analysis techniques were employed.
RESULTS
RESULTS
Fifty-nine patients were found to have LGD. Thirteen patients (22.0%) progressed to either HGD or OAC (10 (16.9%) and three (5.1%) respectively); the annual incidence rates of progression to HGD/OAC and OAC were 5.5% and 1.1% respectively. All patients who developed OAC had non-guideline-adherent surveillance. A Cox model found only two predictors of progression: (i) guideline-adherent surveillance, performed in 16 (27.1%), detected progression to HGD/OAC four times earlier than non-guideline-adherent surveillance (95% confidence interval (CI) = 1.3-12.3; P = 0.016). (ii) The detection of visible lesions at exit endoscopy independently predicted progression (hazard ratio = 6.5; 95% CI = 1.9-22.8; P = 0.003).
CONCLUSION
CONCLUSIONS
Barrett's oesophagus with LGD poses a significant risk of progression to HGD/OAC. Guideline-recommended surveillance is effective, but is difficult to adhere to. Clinical predictors for those who are more likely to progress are yet to be defined.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Whiteman DC, Kendall BJ. Barrett's oesophagus: epidemiology, diagnosis and clinical management. Med J Aust 2016; 205: 317–324.
Singh S, Manickam P, Amin AV, Samala N, Schouten LJ, Iyer PG et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low‐grade dysplasia: a systematic review and meta‐analysis. Gastrointest Endosc 2014; 79: 897–909.e4.
Kendall B. Clinical Practice Guidelines for the Diagnosis and Management of Barrett's Oesophagus and Early Oesophageal Adenocarcinoma [Online]. Australia: Cancer Council Australia; 2014 [updated 2014; cited 2021 May 16]. Available from URL: https://wiki.cancer.org.au/australia/Guidelines:Barrett%27s
Spechler S. Barrett's Esophagus: Epidemiology, Clinical Manifestations, and Diagnosis [Online]. United States: Wolters Kluwer; 2020 [updated 2020; cited 2021 May 16]. Available from URL: https://www.uptodate.com/contents/barretts-esophagus-epidemiology-clinical-manifestations-and-diagnosis
Spechler S. Barrett's Esophagus: Pathogenesis and Malignant Transformation [Online]. United States: Wolters Kluwer; 2020 [updated 2020; cited 2021 May 16]. Available from URL: https://www.uptodate.com/contents/barretts-esophagus-pathogenesis-and-malignant-transformation
Spechler S. Barrett's Esophagus: Surveillance and Management [Online]. United States: Wolters Kluwer; 2020 [updated 2020; cited 2021 May 16]. Available from URL: https://www.uptodate.com/contents/barretts-esophagus-surveillance-and-management
Krishnamoorthi R, Singh S, Ragunathan K, Visrodia K, Wang KK, Katzka DA et al. Factors associated with progression of Barrett's esophagus: a systematic review and meta‐analysis. Clin Gastroenterol Hepatol 2018; 16: 1046–1055.e8.
Kambhampati S, Tieu AH, Luber B, Wang H, Meltzer SJ. Risk factors for progression of Barrett's esophagus to high grade dysplasia and esophageal adenocarcinoma. Sci Rep 2020; 10: 4899.
Maione F, Chini A, Maione R, Manigrasso M, Marello A, Cassese G et al. Endoscopic diagnosis and management of barrett's esophagus with low‐grade dysplasia. Diagnostics (Basel) 2022; 12: 1295.
Konda VJ, Gonzalez Haba Ruiz M, Koons A et al. Complete endoscopic mucosal resection is effective and durable treatment for Barrett's‐associated neoplasia. Clin Gastroenterol Hepatol 2014; 12: 2002–2010.
Wani S, Abrams J, Edmundowicz SA, Gaddam S, Hovis CE, Green D et al. Endoscopic mucosal resection results in change of histologic diagnosis in Barrett's esophagus patients with visible and flat neoplasia: a multicenter cohort study. Dig Dis Sci 2013; 58: 1703–1709.
Desai M, Saligram S, Gupta N, Vennalaganti P, Bansal A, Choudhary A et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus‐related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc 2017; 85: 482–495.
Moss A, Bourke MJ, Hourigan LF, Gupta S, Williams SJ, Tran K et al. Endoscopic resection for Barrett's high‐grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long‐term therapeutic benefit. Am J Gastroenterol 2010; 105: 1276–1283.
Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett's esophagus‐associated esophageal adenocarcinomas. Gastroenterology 2013; 145: 312–319.e1.
Phoa KN, van Vilsteren FG, Weusten BL et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low‐grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209–1217.
Pouw RE, Klaver E, Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R et al. Radiofrequency ablation for low‐grade dysplasia in Barrett's esophagus: long‐term outcome of a randomized trial. Gastrointest Endosc 2020; 92: 569–574.
Qumseya BJ, Wani S, Gendy S, Harnke B, Bergman JJ, Wolfsen H. Disease progression in Barrett's low‐grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta‐analysis. Am J Gastroenterol 2017; 112: 849–865.
Klair JS, Zafar Y, Nagra N, Murali AR, Jayaraj M, Singh D et al. Outcomes of radiofrequency ablation versus endoscopic surveillance for Barrett's esophagus with low‐grade dysplasia: a systematic review and meta‐analysis. Dig Dis 2021; 39: 561–568.
Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360: 2277–2288.
Barret M, Pioche M, Terris B, Ponchon T, Cholet F, Zerbib F et al. Endoscopic radiofrequency ablation or surveillance in patients with Barrett's oesophagus with confirmed low‐grade dysplasia: a multicentre randomised trial. Gut 2021; 70: 1014–1022.
Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol 2022; 117: 559–587.
di Pietro M, Fitzgerald RC, BSG Barrett's guidelines working group. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low‐grade dysplasia. Gut 2018; 67: 392–393.
Statistics about the Population for Australia's Capital Cities and Regions [Online]. Australia: Australian Bureau of Statistics; 2022 [cited 2023 Mar 6]. Available from URL: https://www.abs.gov.au/statistics/people/population/regional-population/latest-release
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.
StataCorp. Stata Statistical Software: Release 17. United States: StataCorp LLC; 2021.
Tsoi EH, Mahindra P, Cameron G, Williams R, Norris R, Desmond PV et al. Barrett's esophagus with low‐grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated. Gastrointest Endosc 2021; 94: 902–908.
Schölvinck DW, van der Meulen K, Bergman JJGHM, Weusten BLAM. Detection of lesions in dysplastic Barrett's esophagus by community and expert endoscopists. Endoscopy 2017; 49: 113–120.
Duits LC, Phoa KN, Curvers WL, ten Kate FJW, Meijer GA, Seldenrijk CA et al. Barrett's oesophagus patients with low‐grade dysplasia can be accurately risk‐stratified after histological review by an expert pathology panel. Gut 2015; 64: 700–706.
Lee SW, Lien HC, Chang CS, Lin MX, Chang CH, Ko CW. Benefits of the Seattle biopsy protocol in the diagnosis of Barrett's esophagus in a Chinese population. World J Clin Cases 2018; 6: 753–758.
Thosani N, Abu Dayyeh BK, Sharma P, Aslanian HR, Enestvedt BK, Komanduri S et al. ASGE Technology Committee systematic review and meta‐analysis assessing the ASGE Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for adopting real‐time imaging‐assisted endoscopic targeted biopsy during endoscopic surveillance of Barrett's esophagus. Gastrointest Endosc 2016; 83: 684–698.e7.
Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S et al. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc 2019; 90: 335–359.e2.
Roumans CAM, van der Bogt RD, Steyerberg EW, Rizopoulos D, Lansdorp‐Vogelaar I, Sharma P et al. Adherence to recommendations of Barrett's esophagus surveillance guidelines: a systematic review and meta‐analysis. Endoscopy 2020; 52: 17–28.
Um PS, Chan MQ, Hinton A, Haisley K, Perry KA, Balasubramanian G. Adherence to surveillance endoscopies posteradication of Barrett's esophagus with high‐grade dysplasia or carcinoma in situ. J Clin Gastroenterol 2023; 57: 459–465.